North America
Kyowa Kirin to Acquire Orchard Therapeutics
Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy
Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million
Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST
Tokyo, London and Boston, October 5, 2023 — Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, tod
05 October 2023
